Revision of Consolidated Business Results Forecast for the First Half of the Fiscal Year Ending March 31, 2026

October 23, 2025

To whom it may concern,

Revision of Consolidated Business Results Forecasts for the First Half of the Fiscal Year Ending March 31, 2026

Takara Holdings (the "Company") announces revisions to the business results forecasts for the first half of the fiscal year ending March 31, 2026 (from April 1, 2025, to March 31, 2026) that it released on May 13, 2025, as stated below.

1. Revised figures for the business results forecast for the first half of the fiscal year ending March 31, 2026 (from April 1, 2025, to September 30, 2025)

   (Millions of yen / %)

   	Net sales	Operating income	Ordinary income	Net income attributable to owners of the parent	Net income per share
   Previous forecast (A) (May 13, 2025, announcement)	191,000	7,800	8,100	7,100	36.36yen
   Revised forecast (B)	186,556	7,786	7,386	5,695	29.40yen
   Change (B－A)	(4,444)	(14)	(714)	(1,405)	-
   Change (%)	(2.3)	(0.2)	(8.8)	(19.8)	-
   Reference: Previous business results (First half of the fiscal year ended March 31, 2025)	176,539	10,532	11,166	9,088	46.55yen

2. Reason for revision

   Net sales for all major segments of the Group-Takara Shuzo, Takara Shuzo International Group, and Takara Bio Group-are now expected to fall below the previous forecasts.

   Operating income is projected to exceed prior forecasts for both Takara Shuzo and Takara Shuzo International Group. However, for the Takara Bio Group, the decline in net sales is expected to have a significant impact, resulting in operating income falling below the previous forecasts.

   Regarding extraordinary income and losses, extraordinary income increased by approximately ¥2.3 billion compared to the previous forecasts due to factors such as the sale of investment securities. On the other hand, the Takara Bio Group recorded an impairment loss of approximately ¥3.9 billion on its facilities, leading to an increase in extraordinary losses.

   Furthermore, after a careful reassessment of the recoverability of deferred tax assets within the Takara Bio Group, approximately ¥400 million of deferred tax assets will be reversed. As a result, net income attributable to owners of the parent of the company is expected to fall below the previous forecasts.

   In addition, today our consolidated subsidiary Takara Bio Inc. (Tokyo Stock Exchange Prime Market, security code number: 4974) also announced revisions of business results forecasts for the first half of the fiscal year ending March 31, 2026.

3. Full-year business results forecast for the fiscal year ending March 31, 2026

The Company is currently evaluating whether revisions of business results forecasts forthe full fiscal year are necessary and considering the details of possible revisions. The Company will make an announcement in this regard when it announces its business results for the first half on November 11, 2025.

* The above-mentioned forecasts have been prepared based on the information available as of the date of announcement of this document and could differ from the business result figures scheduled to be announced on November 11, 2025.

Statements in this document, other than those based on historical fact, concerning the current plans, prospects, strategies and expectations of the Company represent forecasts of future results. While such statements are based on the conclusions of management according to information available at the time of writing, they reflect many assumptions and opinions derived from information that includes major risks and uncertainties. Actual results may vary significantly from these forecasts dueto various factors. Factors that could influence actualresults include, but arenot limited to, economicconditions, especially trends in consumer spending, as well as exchange rate fluctuations, changes in laws and government systems, pressure from competitors' prices and product strategies, declines in selling power of the Company's existing and new products, disruptions to production, violations of the Company's intellectual property rights, rapid advances in technology and unfavorable verdicts in major litigation.